Breast cancer--22nd annual symposium. 8-11 December 1999, San Antonio, TX, USA.
This symposium focused on trials conducted primarily on patients with metastatic breast cancer with the aim of defining the safest and most effective treatment regimens. The combination of paclitaxel and doxorubicin procured a survival advantage, though confirmation of this multicenter randomized data is awaited from other studies. In elucidating the most effective agents to use with trastuzumab (Herceptin; Genentech Inc), results with vinorelbine (Navelbine; Pierre Fabre SA) were most encouraging. Randomized studies of hormonal agents in the adjuvant setting have demonstrated an improved relapse-free survival with goserelin (Zoladex) and anastrozole (Arimidex; both AstraZeneca plc), compared to tamoxifen. Data were presented suggesting tamoxifen leads to a worse outcome when prescribed to pre-menopausal estrogen-receptor negative patients. The use of newer selective estrogen receptor modulators (SERMs) was discussed with particular reference to LY-353381 (Eli Lilly and Co) and fulvestrant (AstraZeneca plc), both of which appear to have impressive profiles of action when compared to tamoxifen.